Alexander S. Pym

Alexander S. Pym

Auto-generated profile, based on publicly available information

Alexander S. Pym

Africa Health Research Institute

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RBR. Brosch
R. Brosch
SGStephen Gordon
Stephen Gordon
MMM. Marmiesse
M. Marmiesse
PBPriscille Brodin
Priscille Brodin
CBC. Buchrieser
C. Buchrieser
SCS. T. Cole
S. T. Cole
The distribution of 20 variable regions resulting from insertion-deletion events in the genomes of the tubercle bacilli has been evaluated in a total of 100 strains of Mycobacterium tuberculosis , Mycobacterium africanum , Mycobacterium canettii , Mycobacterium microti , and Mycobacterium bovis . This approach showed that the majority of these polymorphisms did not occur independently in the different strains of the M. tuberculosis complex but, rather, resulted from ancient, irreversible genetic events in common progenitor strains. Based on the presence or absence of an M. tuberculosis specific deletion (TbD1), M. tuberculosi s strains can be divided into ancestral and “modern” strains, the latter comprising representatives of major epidemics like the Beijing, Haarlem, and African M. tuberculosis clusters. Furthermore, successive loss of DNA, reflected by region of difference 9 and other subsequent deletions, was identified for an evolutionary lineage represented by M. africanum , M. microti , and M. bovis that diverged from the progenitor of the present M. tuberculosis strains before TbD1 occurred. These findings contradict the often-presented hypothesis that M. tuberculosis, the etiological agent of human tuberculosis evolved from M. bovis , the agent of bovine disease. M. canettii and ancestral M. tuberculosis strains lack none of these deleted regions, and, therefore, seem to be direct descendants of tubercle bacilli that existed before the M. africanum→M. bovis lineage separated from the M. tuberculosis lineage. This observation suggests that the common ancestor of the tubercle bacilli resembled M. tuberculosis or M. canettii and could well have been a human pathogen already.

21 August 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ADAndreas H. Diacon
Andreas H. Diacon
APAlexander Pym
Alexander Pym
MGMartin P. Grobusch
Martin P. Grobusch
JRJorge M. de Los Rios
Jorge M. de Los Rios
EGEduardo Gotuzzo
Eduardo Gotuzzo
BDBrian Dannemann
Brian Dannemann
Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial ATP synthase, has been associated with accelerated sputum-culture conversion in patients with multidrug-resistant tuberculosis, when added to a preferred background regimen for 8 weeks.

4 June 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ADAndreas H. Diacon
Andreas H. Diacon
APAlexander Pym
Alexander Pym
MGMartin Grobusch
Martin Grobusch
RPRamonde Patientia
Ramonde Patientia
RRRoxana Rustomjee
Roxana Rustomjee
DNDavid F. Mc Neeley
David F. Mc Neeley
The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase. TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis.

31 October 2002 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
APAlexander S. Pym
Alexander S. Pym
PBPriscille Brodin
Priscille Brodin
RBRoland Brosch
Roland Brosch
MHMichel Huerre
Michel Huerre
SCStewart T. Cole
Stewart T. Cole
Summary: Although large human populations have been safely immunized against tuberculosis with two live vaccines, Mycobacterium bovis BCG or Mycobacterium microti, the vole bacillus, the molecular basis for the avirulence of these vaccine strains remains unknown. Comparative genomics has identified a series of chromosomal deletions common to both virulent and avirulent species but only a single locus, RD1, that has been deleted from M. bovis BCG and M. microti. Restoration of RD1, by gene knock‐in, resulted in a marked change in colonial morphology towards that of virulent tubercle bacilli. Three RD1‐encoded proteins were localized in the cell wall, and two of them, the immunodominant T‐cell antigens ESAT‐6 and CFP‐10, were also found in culture supernatants. The BCG::RD1 and M. microti::RD1 knock‐ins grew more vigorously than controls in immunodeficient mice, inducing extensive splenomegaly and granuloma formation. Increased persistence and partial reversal of attenuation were observed when immunocompetent mice were infected with the BCG::RD1 knock‐in, whereas BCG controls were cleared. Knocking‐in five other RD loci did not affect the virulence of BCG. This study describes a genetic lesion that contributes to safety and opens new avenues for vaccine development.

14 April 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
APAlexander S. Pym
Alexander S. Pym
PBPriscille Brodin
Priscille Brodin
LMLaleh Majlessi
Laleh Majlessi
RBRoland Brosch
Roland Brosch
CDCaroline Demangel
Caroline Demangel
SCStewart T. Cole
Stewart T. Cole

1 June 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ADA. H. Diacon
A. H. Diacon
PDP. R. Donald
P. R. Donald
APA. Pym
A. Pym
MGM. Grobusch
M. Grobusch
RPR. F. Patientia
R. F. Patientia
DMD. F. McNeeley
D. F. McNeeley
The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline TMC207, recently renamed bedaquiline, or placebo, added to the first 8 weeks of a background regimen, are presented. Bedaquiline significantly reduced the time to culture conversion over 24 weeks (hazard ratio, 2.253; 95% confidence interval, 1.08 to 4.71; P = 0.031). With the exception of nausea reported in 26% of patients receiving bedaquiline and none receiving placebo, adverse events occurred at similar frequencies in both groups of patients: bilateral hearing impairment, extremity pain, acne, and noncardiac chest pain occurred in 13 and 21%, 17 and 13%, 9 and 17%, and 4 and 17% of patients, respectively, receiving bedaquiline or placebo. Excluding resistance to ethambutol and ethionamide, only one patient receiving bedaquiline acquired resistance to companion drugs, but five patients receiving placebo (4.8% versus 21.7%; P = 0.18) acquired resistance to companion drugs, and resistance to ofloxacin was acquired in four patients receiving placebo and none receiving bedaquiline (0% versus 22%; 0 = 0.066). In all, 23 patients (49%), including 13 receiving placebo (54%) and 10 receiving bedaquiline (44%), discontinued the study prior to its completion, 12 during the first 24 weeks of treatment. Eight subjects were withdrawn for noncompliance or default, and seven withdrew consent, citing the rigorous program of investigations for safety and pharmacokinetic monitoring. Bedaquiline may contribute to the management of multidrug-resistant tuberculosis by effecting more rapid sputum culture negativity and by preventing acquired resistance to companion drugs.